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Abstract: Knowing insulin sensitivity (SI) can optimise glycaemic control, assess metabolic drug therapy, 
or define diabetes risk. The DISTq is a short, low dose IM-IVGTT that generates an estimate of SI 
immediately after a 40 minute test using only glucose measurements, subject’s physical attributes, and 
population parameter estimations. In this article, the DISTq is evaluated in clinical and in silics trials. In 
clinical trials, the test has shown a very strong correlation to the fully sampled DIST SI (R=0.91), (which 
also uses insulin and c-peptide assays) and a strong correlation to the euglycemic hyperinsulinaemic clamp 
(EIC) in in silico virtual trials (R=0.89). This study shows that population estimates can reduce the need 
for expensive insulin and c-peptide assays in obtaining an accurate, real-time estimation of SI. 
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1. INTRODUCTION 
Insulin resistance (IR) has been widely accepted as a strong 
indicator of an individuals risk of type 2 diabetes (T2DM) 
(DeFronzo & Ferrannini 1991; Ferrannini 1997). A 10-year 
study of T2DM development has shown that subjects that 
later develop diabetes have a 60% higher IR than average. 
(Martin et al. 1992). IR is also a strong predictor of T2DM 
and of cardiovascular disease (McLaughlin et al. 2007). 
Accurate estimation of IR could be used to promote needed 
lifestyle changes that could drastically reduce the incidence of 
hyperglycaemia and cost associated with T2DM (Santaguida 
et al. 2005). 
The various tests used to estimate insulin sensitivity (SI, 
SI=IR-1) use various methods to provoke and measure the 
subject’s glycaemic responses (Ferrannini & Mari 1998; 
Pacini & Mari 2003). The euglycemic hyperinsulinaemic 
clamp (EIC) aims to suppress endogenous glucose production 
(EGP) and partially suppress endogenous insulin production 
(Uen) (DeFronzo et al. 1979). In contrast, the intravenous 
glucose tolerance test (IVGTT) promotes Uen (Pacini & 
Bergman 1986). Hence, while the parameters derived by these 
tests are similar, they are not equivalent. An ideal parameter 
for clinical or diagnostic use would measure the efficiency of 
insulin to dispose of glucose to the periphery at sensible 
glucose and insulin concentrations.   
The gold standard for SI testing is the EIC. This measures the 
rate of glucose disposal at basal glucose with a saturative level 
of insulin. The EIC is extremely accurate (DeFronzo et al. 
1979), but it takes 4-5 hours and approximately 10 clinician 
hours (2 clinicians). A result is not guaranteed with an 
inexperienced clinician. 
The IVGTT measures the subject’s response to a 20-25g 
intravenous (IV) glucose bolus with very frequent 1-3 minute 
sampling. Some protocols modify the response with a 2-3U 
IV bolus of insulin following the glucose bolus (IM-IVGTT) 
(Pacini & Mari 2003). SI is obtained using the minimal model 
(Bergman et al. 1979). The boluses in this test tend to be 
supra-physiological and the trial takes 2-3 hours.  
Cheaper surrogate tests include fasting glucose, 2-hour 
glucose (2-hr OGTT) and homeostasis model assessment 
(HOMA). Fasting glucose allows a diagnosis of T2DM 
(Tominaga 1999), but does not offer any estimates of SI. 
Intervention is desirable prior to impaired fasting glucose, 
which is a symptom of the subject’s inability to maintain 
glycaemic homeostasis. Hence, fasting glucose is not an 
effective screening tool. 
The 2-hr OGTT measures the subject’s ability to dispose a 
large glucose load which is administered orally. 2 hours after 
the ingestion of the glucose load the blood glucose 
concentration is measured to allow a diagnosis of T2DM. 
HOMA is a fasting insulin and glucose test. Subjects with low 
sensitivity will require more insulin to maintain glycaemic 
homeostasis. This test has a inconsistent correlation with the 
clamp (R=-0.19 → R=-0.82) (Bonora et al. 2000; Mari et al. 
2001) and does not fully represent insulin-glucose dynamics. 
The dynamic insulin sensitivity test (DIST) is a short, 
infrequently sampled, low dose IM-IVGTT. The test takes 30-
45 minutes to administer. Glucose, insulin and c-peptide data 
are used with a clinically validated physiological model (Lotz 
et al. 2005). The model and data provide parameters for Uen, 
insulin clearance rate, and SI. The test has shown good 
correlation to the EIC in virtual trials (R=0.99) (Lotz et al. 
Proceedings of the 7th IFAC Symposium on Modelling
and Control in Biomedical Systems, Aalborg, Denmark,
August 12 - 14, 2009
WeFT1.6
"The material submitted for presentation at an IFAC
meeting (Congress, Symposium, Conference, Workshop)
must be original, not published or being considered
91
 
 
     
 
2008), and high repeatability in a clinical pilot study (Δ= 6%) 
(Lotz 2007b). 
This paper presents an alternative method (DISTq – quick 
DIST) for solving DIST data using only glucose samples and 
the subjects’ physical attributes (height, weight, sex, and age). 
Glucose samples can be assayed at the bedside, thus the 
sample cost is extremely low and DISTq can provide SI 
immediately. To achieve this, the insulin concentrations in the 
plasma and interstitium must be estimated using knowledge 
available at testing. Parameter relationships derived from 
clinical DIST pilot study data (Lotz 2007b) can be used to 
generate the required estimates. The loss of insulin and c-
peptide data allows estimation of SI, but unique estimation of 
Uen and insulin clearance is no longer possible. 
2. METHOD 
The data used in this paper was generated by the DIST test 
clinical pilot study conducted by (Lotz 2007a). Patient 
characteristics ranged from healthy lean individuals to 
individuals with T2DM, details can be found in Lotz (2007).  
 2.1 DIST Test protocol 
Subjects fasted from 10pm the night before. A cannula was 
placed in the antecubital fossa to enable blood sampling and 
deliver boluses. Blood samples were taken at 0, 10, 15, 20, 25, 
30, 35, 40, 50 minutes. A glucose bolus (50% dextrose, 50% 
saline), was given to the subject immediately after the t=10 
sample. An insulin bolus (actrapid) was given immediately 
after the t=20 minutes sample. Three different dosing 
protocols were used:  
• Low dose:  5g glucose,  0.5U insulin  
• Medium dose:  10g glucose,  1U insulin  
• High dose:  20g glucose,  2U insulin  
The DIST pilot study consisted of 2 parts. Part 1 measured the 
intra-dose repeatability whereas the part 2 measured the inter-
dose repeatability. Hence, some subjects underwent 2-3 trials 
at the same dose and some underwent 2-3 trials with 2 dosing 
protocols. Full details can be found in Lotz (2007).  Blood 
samples were assayed for plasma glucose, insulin and C-
peptide concentrations. Glucose was analysed by an 
enzymatic glucose hexokinase assay (Abbott). Insulin and C-
peptide were analysed with an ECLIA immunoassay (Roche 
Diagnostics Elecsys, Germany). 
2.2 Physiological model equations 
The physiological model used to describe the dynamics found 
in the test is expressed by Equations 1-5. Equations 1 and 2 
were first published in Van Cauter (1992) and enable 
estimation of insulin secretion from the deconvolution of c-
peptide concentrations. The (Sherwin et al. 1974) model to 
describe insulin dynamics was simplified to Equations 3 and 4 
by Lotz (2007). Equation 5 is a development of the minimal 
model representation of glucose (Bergman et al. 1979) by 
(Chase et al. 2005). In contrast to the typical use of the 
minimal model, Equation 5 increases the identifiably of SI by 
fixing the pgu term to a population average.  
 1 
  2 
 3 
  4 
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Where: k1, k2, k3, nK, nL, nI, and nC are rate parameters (min-1); 
αI is the liver clearance saturation coefficient (I-1); C and Y are 
plasma and interstitial compartment C-peptide (pmol.L-1); Uen 
is the endogenous insulin production rate (pmol.min-1); I and 
Q are plasma and interstitial compartment insulin (mU.L-1); 
Uex and P are the insulin and glucose boluses (g and mU); Vp 
and Vq are volumes of distribution (L); xL is the first pass liver 
extraction (%); G is the blood-glucose concentration (mmol.L-
1); Ge and Qb are basal levels of the respective species; Vg is 
the volume of distribution of glucose (L); and pgu is the non-
insulin mediated glucose disposal rate (min-1) 
2.3 Data analysis 
The DISTq method uses only glucose data from the DIST test 
protocol to estimate an SI. Without knowledge of insulin there 
is an incomplete representation of the pharmaco-kinetics of 
the insulin-glucose system, however, SI estimation is only 
possible with the subject’s specific insulin concentration and 
rate of glucose disposal. To provide a value for SI without 
insulin data requires accurate prediction of insulin 
concentrations using population derived values.  
Every full DIST test produced profiles for insulin decay and 
endogenous insulin production that had certain common 
features. The magnitude of the features varied, but the form of 
these features is consistent. Figure 1 shows the ten important 
characteristics required to define a subject’s insulin 
concentrations during a test. 
 
Figure 1 Unknown features that define the concentration of 
insulin (right), and endogenous production (left) in the subject 
Some characteristics can be derived from the DIST protocol 
or from assumptions of the full DIST model: 
2.The first phase pancreatic insulin release occurs 
immediately after the glucose bolus (Pacini & Mari 2003)  
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6. The effect of the first phase pancreatic response on the 
insulin concentrations in plasma is known once the first 
phase response is defined. First pass liver extraction xL is 
set at 70% and is not a variable in this method (as it is in 
the full DIST methods). 
7. The time of the insulin bolus is recorded per the protocol. 
8. The maximum insulin concentration in the plasma is found 
by dividing the known bolus mass by the volume of 
distribution of plasma (as estimated by (Van Cauter et al. 
1992)). 
10. The insulin transport rate to the interstitial fluid is defined 
by kinetic parameters from (Van Cauter et al. 1992). 
Other characteristics cannot be easily estimated: 
1. Basal endogenous insulin production rate (UB). 
3.  The magnitude of the first phase response (Umax). 
4.  The magnitude of the second phase response (Uave). 
5.  Basal insulin concentration in the plasma (IB). 
9.  Liver clearance rate of insulin in plasma (nL). 
The full data set from the pilot study was solved using an 
iterative integral method (Hann et al. 2005)and the methods 
described by (Lotz 2007a). The parameters that cannot be 
defined with only glucose data were identified and stored to 
aid in the generation of population-based relationships. 
Typically, researchers try to develop a-priori relationships 
between parameters (i.e. parameter = f(BMI, BSA, …)) 
However, no mathematical transform was apparent to 
linearise the relationship between BMI, or any similar a-priori 
metric, to these unknowns. However, when these parameters 
are solved for using the full DIST method and compared to SI, 
relationships that can be mathematically expressed are 
observed (Figure 2). A-posteriori identification of these 
unknowns with SI is reasonable. 
A power relationship exists between SI and IB, UB, Umax, and 
Uave. Although the relationship between SI and Umax is less 
strong, this variation is mitigated by the DISTq process. The 
liver clearance rate is best represented with a log relationship 
to SI. The mean percentage error between the measured 
metrics and the a-posteriori predicted metric was 36%. Figure 
2 and equations 6-10 show these f(SI) relationships. 
 6 
 7 
 8 
 9 
 10 
The DISTq method is iterative. The first iteration uses 
parameter estimates calculated with a population average SI 
of 10 e-4 L.mU-1.min-1 and Equations 6-8 to provide sufficient 
assumptions to generate an endogenous insulin production 
curve. Equations 9 and 10 along with the endogenous insulin 
production curve and insulin bolus knowledge provide 
sufficient information to simulate an insulin decay curve. 
With the interstitial insulin profile generated, the real glucose 
data can be used to solve Equation 5 for SI. This estimated SI 
value allows new parameter estimations from Equations 6-10.  
 
Figure 2 the a-posteriori relationships between the unknown 
parameters and SI which have been developed using (N=46) 
fully sampled DIST tests 
The process of estimating an endogenous insulin reaction, 
simulation of insulin decay, and solving for SI is repeated 
until convergence is achieved. Typically five iterations are 
required. 
The basic DISTq method does not fit the shape of the glucose 
decay. However, after a DISTq SI is found, the estimation can 
be improved if the high resolution of the glucose decay is 
utilised. To use the information in this region, nL is allowed to 
vary up to 20% from its population assumed value. The 
insulin concentration profile is re-simulated using nL values 
between 0.8nL and 1.2nL, the value that allows the best 
glucose re-simulation fit to the measured data is used in a 
final estimation of SI. This is a second cycle of the algorithm. 
The DISTq SI is compared to the SI estimated by the full 
DIST data sets.  
2.4 DISTq Analysis 
To establish whether the DISTq is capable of estimating SI 
using only glucose data, SIDISTq will be compared to the fully 
sampled SIDIST with a Pearson correlation. 
A Monte Carlo simulation of an EIC cohort was designed 
matching the process of (Lotz et al. 2008). The simulation 
included a HOMA analysis as well as a full DIST and glucose 
only DISTq analysis. The EIC data was from 146 clamp tests 
(73 subject intervention study by (McAuley et al. 2002)). The 
Monte Carlo analysis used SI values from this cohort Lotz 
(2008) to run, in silico, DIST and DISTq tests with random 
physiological variations in sample concentration and bolus 
volumes (per Lotz et al. 2008). In full, 250 iterations were 
completed for each subject. Random assay error was added to 
the base data in accordance with (Lotz et al. 2008). The mean 
and standard deviation of SI for each trial set and solver 
method was stored. The coefficient of variation (CV, 
CV=STD/mean) was calculated. 
The 73 subjects participated in 2 clamp tests before and after 
an 16 week intervention (McAuley et al. 2002). Relative 
changes in SI for each patient were calculated: 
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The changes in SI for the real clamp and HOMA, and the 
virtual DIST and DISTq were thus evaluated and ranked in 
the order of improvement as recorded by the clamp test.  
3. RESULTS 
The DISTq showed a strong ability to replicate the SI of the 
fully sampled DIST test using clinically derived data. The 
DISTq SI showed strong equivalence with the fully sampled 
DIST (Rpearsons=0.86). When the liver clearance parameter was 
varied in the second algorithm cycle, the correlation increased 
(R=0.91). Figure 3 shows the strength of relationship between 
the DIST and the DISTq.  
 
Figure 3 correlation between SIDIST and SIDISTq using clinically 
derived DIST data 
 
Figure 4 in-silics comparison between the DIST, DISTq and 
HOMA and ISIg form the clinical clamp study  
Correlation between ISIg and the DIST matched Lotz et al 
(2008) R=0.98. The simulation also predicted a correlation 
between ISIg and the DISTq was R=0.89. The correlation 
between DIST and DISTq was slightly better than the clinical 
result, with R=0.96. The HOMA correlation to ISIg was 
significantly lower at R=-0.37.  
Figure 5 confirms that the DIST and DISTq were able to 
accurately capture the intra-subject SI shifts with correlations 
to the ISIg recorded shifts of 0.97 and 0.92 respectively. 
HOMA showed an inability to define these shifts (R=-0.22). 
 The Monte Carlo simulation resulted in an average CV=6.6% 
for the full DIST, comparable to that found by (Lotz et al. 
2008). The average CV=21.2% of DISTq was considerably 
higher. Figure 6 shows a marginal increase in CV at the lower 
end of the SI scale. 
 
 
Figure 5 in-silics intra-subject shift in SI compared against 
ISIg  
 
Figure 6 Coefficient of variation distribution derived by the 
Monte Carlo simulation 
4. DISCUSSION 
The DISTq method for estimating SI using only glucose data 
from the DIST protocol has shown a strong equivalence to the 
fully sampled DIST (R=0.86). This correlation can be 
improved by varying the liver clearance parameter in a second 
algorithm step (R=0.91). This high correlation is of significant 
importance, as it shows the ability to estimate SI using only 
glucose data and physical attributes. 
DISTq can give a good estimation of SI. The method is 
dependant on glucose data and a series of assumptions on 
insulin concentration that are well justified in the literature. 
However, the population-derived parameter assumptions in 
Figures 2 may not be as valid given the smaller numbers used 
to derive them and resulting wider confidence bands. This 
weakness is likely diminished by the assumptions driven by 
the protocols use of insulin boluses that can mask some of the 
likely uncertainties. Thus, the DISTq method performs well, 
but greater numbers of subjects and with matching full DIST 
results would solidify the level of confidence in the parameter 
estimation step.  
The DISTq CV was greatest in the low SI range due to the 
higher than usual variance of the unknown parameters in this 
region. This is evident in figure 2, particularly for the Umax 
metric. Newly diagnosed and long term T2DM individuals 
have a similar SI levels. However the endogenous insulin 
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output and Umax are elevated in a newly diagnosed and 
diminish the long term T2DM.. This causes a trumpet in the 
parameter relationship data shown in figure 2 for Umax and 
Ub at low SI. More data may be required in this region to 
solidify our estimates.  
For a new test to be accepted as a viable option, it must have a 
strength over tests of similar cost (in this case HOMA or 
OGTT). The DISTq is a very cheap test in terms of assay cost, 
and time; however, it is more intensive in terms of clinician 
activity than the OGTT or the HOMA. For DISTq to be 
accepted as a viable option for use it must show greater 
accuracy in terms of repeatability and correlation to the EIC 
than either the HOMA or OGTT. 
Figure 4 shows that DISTq was able to detect intra-subject 
shifts in SI after a 3 month intervention, whereas HOMA 
showed a clear inability to do so. The virtually derived DISTq 
SI correlated well to the EIC (R=0.81) compared to the 
HOMA (R=-0.37). This result implies that the DIST and 
DISTq are more equivalent to the EIC than HOMA.  
(Ferrannini et al. 2005) found a R=0.74 correlation between 
the 2-hour oral-glucose tolerance test (OGTT) and the clamp 
which is comparable to our in silico correlation of R=0.81. 
However, the reproducibility of the OGTT has been called 
into question by a number of researchers who found NGT, 
IGT and T2DM re-classification rates of only 50-65% (Ko et 
al. 1998; Levy et al. 1999; Park et al. 2000).  
The DISTq contrasts with the OGTT by the way in which 
insulin and glucose are elevated in the test subject. Insulin is 
not measured in either test, but the DISTq protocol introduces 
a known amount of insulin at a set time, which can still 
account for the majority of the subject’s plasma insulin. This 
approach allows strong predictions of the insulin 
concentration that are not possible in the OGTT protocol. A 
relative indifference to insulin measurements causes the 
metric derived by the OGTT to be more about glucose 
disposal than a SI. Thus, this OGTT metric can be useful in 
some cases, but is not ideal in clinical studies where an 
accurate estimation of peripheral SI is important.  
The DISTq protocol requires the subject to be present for 
approximately an 30-60 minutes and, as the test requires an 
insulin bolus, must be supervised by a doctor. In contrast, 
HOMA is a single blood test, and the OGTT requires only a 
nurse to administer a glucose drink and take a blood test two 
hours later. Like the OGTT the DISTq can give an answer 
immediately after the final blood test, where HOMA requires 
a costly insulin assay, which may take a few days. Hence, the 
DISTq balances intensity, time and resolution. 
The full DIST test derived SI correlates somewhat better than 
the DISTq to the EIC and the c-peptide assay provides unique 
identification of Ub, Umax and Uaverage which is an indicator of 
beta-cell function. The subject’s beta-cell function along with 
SI is a very strong predictor of the patients current risk in 
terms of the progression to type 2 diabetes (Mari et al. 2008). 
Hence, DIST is a stronger diagnostic but less cost efficient 
screening tool. 
The validation of the method has been completed on the same 
data set that was used to derive the parameter estimation 
equations. Intuitively, this would increase the correlation 
expected between DIST and DISTq. This concern is offset 
when considering that the data set was a clinically derived so 
the predicted profiles for insulin and c-peptide are 
representations of actual population characteristics. The 
parameter relationships shown in figure 2 are noisy and no 
effort is taken to fit that noise. If the noise was fitted with 
complex multivariable equations this argument would be 
more valid. However, as just the general form of the 
relationships is developed, validating with the derivation set is 
valid for this first analysis. 
The DISTq is likely to be a useful test where a working 
knowledge of the insulin sensitivity of a subject is required 
quickly. This situation can arise in an intensive care situation 
when optimal glycaemic regulation (Shaw et al. 2006) or an 
indicator of sepsis (Blakemore et al. 2008) is desired. As it is  
inexpensive and relatively accurate, it may also prove to be a 
suitable screening tool for the assessment of diabetes risk 
(Harris et al. 2003) or for analysing sensitivity changes in a 
drug or intervention study. It could also be used with newly 
diagnosed diabetic individuals to understand their current 
sensitivity to better control their condition with insulin. 
5. CONCLUSION 
When choosing an insulin sensitivity test the clinician or 
researcher should decide what level of resolution, intensity, 
cost, complexity, speed and confidence is best for that 
particular application or study. The DISTq is not an answer 
for all of these purposes, but should be considered when a low 
intensity, very inexpensive, but relatively accurate estimation 
of SI is desired. The low cost and intensity may allow greater 
numbers to be studied or tested. The test requires advanced 
mathematical processes, but once this is provided, the data 
can be analysed in real-time and the researcher or clinician 
can thus get a result immediately.  
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